echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > ESMO 2022: Prediction of growth centers, MYC/BCL2 protein bi-expression status, and MYC gene rearrangement in patients with diffuse large B-cell lymphoma (DLBCL) based on machine learning (LYSA study)

    ESMO 2022: Prediction of growth centers, MYC/BCL2 protein bi-expression status, and MYC gene rearrangement in patients with diffuse large B-cell lymphoma (DLBCL) based on machine learning (LYSA study)

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor with diffuse growth of tumoric large B lymphocytes, diffuse nodular structure destruction or infiltration of large B lymphoid cells, with a high degree of heterogeneity and invasiveness, the R-CHOP regimen can only cure about 70% of patients, about 30-40% of patients are resistant or relapse, and the prognosis is poor


    Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults, accounting for about (30-40%)


    Currently, the WHO divides DBBCL into germination center B cell-like (GCB), activated B-cell-like (ABC) and type III DLBCL (Type 3 DLBCL


    Recently reported in ESMO 2022, the use of machine learning for analysis analyzed 565 full-slice images (WSI) stained with hematoxylin/eosin in the dataset of the LYSA trial "GHEDI" (Deciphering the Genetic Heterogeneity of RITUXIMAB-era DLBCL


    The results showed that the ROC AUC obtained by the DL model was 0.


    This study demonstrates the predictive power of DL applied to WSI to predict DLBCL subtypes, and this predictive model can be used to improve pathologists' analytical capabilities, especially when IHC staining or FISH is not available


    Related Stories:

    NEJM: Landmark study: A more precise step in the classification of diffuse large B-cell lymphoma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.